Conclusion
NSCLC, non‐small cell lung cancer, adverse drug reactions, cancer cachexia
ADVERSE DRUG REACTIONS, NSCLC
This study of NSCLC patients with cancer cachexia revealed consistent improvements in LBM, body weight, and appetite across most subgroups of anamorelin‐treated patients. This study also demonstrated the tolerability of anamorelin regardless of age and PS, with a low incidence of serious ADRs in each subgroup.We performed post‐hoc analyses of the ONO‐7643‐04 study to investigate the efficacy and safety of anamorelin in subgroups of Japanese patients with non‐small cell lung cancer. This study revealed consistent improvements in lean body mass, body weight, and appetite score using QOL‐ACD item 8 across most subgroups of anamorelin‐treated patients versus placebo. This study also demonstrated the tolerability of anamorelin regardless of age and performance status, with a low incidence of serious adverse drug reactions in each subgroup.
